StockCode
688506
Investors
中文
|
EN
About Biokin
Founder
Innovative Pharmaceutical Company Synchronizing R&D,
Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
Systimmune
Baili Pharm/Baili-Bio
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Complete Marketing System
Drugs for Pediatrics
Cardiovascular Disease
Anesthetics&Sedatives,,Severe illness
Chronic Diseases
Social Responsibility
Earthquake Relief
Caring Donation
Paying Taxes in Accordance with Law
Charity and Public Welfare
Career Development
Talent Recruitment
Join Us
Pharmacovigilance
Contact
About Biokin
Innovation and R&D
Manufacturing and Quality Control
Product and Marketing
Social Responsibility
Career Development
Pharmacovigilance
Contact
NEWS RELEASES
2023
05-04
The World’s Leading Oncologists Joined the Clinical Science Advisory Council of SystImmune, a North American Subsidiary of BIOKIN Pharmaceutical
05-04
ASCO 2023|Presentation of Results of Five BIOKIN Pharmaceutical Clinical Studies
03-10
SI-B001（EGFR x HER3）Initiating Phase III Clinical Trial
02-02
New Year’s Speech by the President: “One Step a Footprint, One Step a Realm, Be the Peak of the High Mountain”
01-09
Biokin Pharmaceutical Being Formally Listed on Science and Technology Innovation Board of Shanghai Stock Exchange
01-08
Professor Zhangli: Preliminary Data of Clinical Trial of EGFR×HER3 Bispecific Antibody ADC Drug is Encouraging, Precise Treatment of Lung Caner being Furthered Improved
01-08
Professor Zhang Jian: EGFR×HER3 Bispecific Antibody ADC Drug Aiming At Solveing The Hard Problem of HER2 Drug Resistance, Shows Satisfactory Curative Effects In Preliminary Clinical Data!
01-07
Professor Li Wenbin：The First Clinical Study on GBM by Tetra-specific Antibody Drug Immunotherapy May Change the Survival Situation of the Patients alive with tumour
01-06
Exclusive Interview of Professor Shen Lin｜With Bispecific Antibody ADC Drugs Emerging, Therapy of Gastrointestinal Tumors Going with Double Pace
2022
11-08
Named Exemplar IP Generating Entity on November 08, 2022
11-07
Received provincial certification as the “Technological Innovation Exemplar Entity”
07-01
Received full drug approval on June 28, 2022, for Anbeixin®Enalapril Maleate Oral Solution .
04-28
Launched “Baili Against the Pandemic, Part II” to support the anti-pandemic efforts on April 28, 2022.
02-25
Certified as a “National Enterprise Technology Center” on February 25, 2022
02-11
The First “TCM Culture and Tonifying Qi Festival” Being About to be Held with Great Ceremony
02-11
On February 11, 2022, Systimmune, Inc. named Doctor Martín Sebastian Olivo as its Chief Medical Officer
01-27
Biokin Pharmaceuticals Being Ranked in the List of "Top 100 Enterprises for Technological Innovation and Development Capability in Sichuan in 2021”
01-14
Chairman Zhu Yi Being Selected for Tianfu Entrepreneurship Leading Talents Project in “Tianfu Qingcheng Program” in 2021
BACK
Systimmune
Baili Pharmaceutical
Guorui Pharmaceutical
Baili-Bio
Jingxi Pharmaceutical
Hiatt Technology
Company Address：1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City
Postcode：610041
Tel：028-85183639
Sichuan Biokin Pharmaceuticals Co.,Ltd Copyright © 2018 All rights reserved
SICPB No. 17035664-1
Internet Drug Information Service Qualification Certificate S/N: (C)-FJYX-2022-0343
CGWAB No.51011502000517
